HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk

June 2022

Achieving Greater Diversity in Dementia Research: A Call to Action

June 20, 2022

Letter From the Editor

Achieving greater diversity in study populations is a focus of increasing scrutiny, priority, and funding in all medical research, including studies enrolling individuals on the continuum of prodromal Alzheimer disease, mild cognitive impairment, and Alzheimer disease.

New Treatments in Migraine: An In-Depth Review

June 16, 2022


Although new treatments and innovations are a sign of growth in migraine care, it is important to realize that growth comes with a certain amount of pain. In clinical practice, choosing the right treatment option for patients in a time-limited visit is often a dilemma.

Endoplasmic Reticulum and/or Mitochondrial-Dependent Neuronal Degeneration in ALS

June 14, 2022


Given the importance of mitochondrial and endoplasmic reticulum function in ALS, the disruption of intracellular mitochondria-endoplasmic reticulum contacts presents yet another avenue for neuronal degeneration—perhaps the primary point of underlying dysfunction.

The Aducanumab Saga and the Future of Antiamyloid Monoclonal Antibodies

June 13, 2022

Cover Story

The journey of aducanumab (Aduhelm; Biogen) from development to the FDA is a tortured one, but its path may serve to teach the Alzheimer disease field valuable lessons as it strives forward to develop disease-modifying therapies.

National Institutes of Health Launches Phase 1 Trial to Study Epstein-Barr Virus Vaccine

May 06, 2022

In the Headlines

The early-stage clinical trial will include 40 healthy volunteers to evaluate the safety and immune response of an investigational EBV gp350-Ferritin nanoparticle vaccine with a saponin-based Matrix-M adjuvant.

CNM-Au8 Shows Survival Benefit for Patients With ALS in Phase 2 Extension

April 02, 2022

Conference Coverage

Interim data from the phase 2 RESCUE-ALS trial open-label extension suggest that Clene Nanomedicine’s investigational agent, CNM-AU8, offered benefits to patients with ALS in terms of survival, in addition to prior results suggestive of slowed progression.